Evaluating the Efficacy and Safety of Long-Acting GLP-1 Receptor Agonists in T1DM Patients
(1) Background: Glucagon-like peptide 1 receptor agonists (GLP-1 RA) are a class of therapeutic agents that mimic the endogenous incretin hormone GLP-1. While this class of agents is not approved for Type 1 Diabetes (T1DM) due to concern of increased diabetic ketoacidosis (DKA) risk, long-acting GLP...
| Main Authors: | , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
MDPI AG
2023-02-01
|
| Series: | Endocrines |
| Subjects: | |
| Online Access: | https://www.mdpi.com/2673-396X/4/1/8 |
| _version_ | 1797612200251097088 |
|---|---|
| author | Deene Mohandas Jamie Calma Catherine Gao Marina Basina |
| author_facet | Deene Mohandas Jamie Calma Catherine Gao Marina Basina |
| author_sort | Deene Mohandas |
| collection | DOAJ |
| description | (1) Background: Glucagon-like peptide 1 receptor agonists (GLP-1 RA) are a class of therapeutic agents that mimic the endogenous incretin hormone GLP-1. While this class of agents is not approved for Type 1 Diabetes (T1DM) due to concern of increased diabetic ketoacidosis (DKA) risk, long-acting GLP-1 medications are being commonly prescribed off label for T1DM in clinical practice. Several studies addressed the efficacy and safety of short-acting GLP-1 agonists therapy in patients with T1DM, but the data on long-acting agents are lacking. In our study, we aim to fill in this gap and help healthcare providers in their clinical decision making on the use of these agents for T1DM patients. (2) Methods: We conducted a retrospective chart review of T1DM patients on a long-acting GLP-1 for at least six months. Our retrospective chart review included information starting two years prior to starting GLP-1, and six or more months after starting GLP-1. Parameters collected included HbA1c, 14-day Continuous Glucose Monitor (CGM) and blood glucose (BG) data, and metabolic data (weight, systolic and diastolic blood pressure, and cholesterol levels). Statistical analysis was conducted using paired t-tests on R and Excel with α of 0.05. (3) Results: Our cohort consisted of 54 participants with T1DM on a long-acting GLP-1 (semaglutide, dulaglutide, exenatide extended-release [ER], albiglutide). Mean GLP-1 treatment duration was 23.85 ± 15.46 months. HbA1c values decreased significantly by an average of 0.71% percentage points (%-points, <i>p</i> = 0.002) comparing pre-therapy vs. on GLP-1 treatment. Similarly, for pre-therapy vs. on GLP-1 treatment values, CGM results were significant for increased time in range by 12.15%-points (<i>p</i> = 0.0009) showing a decreased average time in hyperglycemia (BG > 180 mg/dL) by a mean difference of 11.97%-points (<i>p</i> = 0.006), decreased 14-day mean BG by 19 mg/dl (<i>p</i> = 0.01), decreased 14-day BG standard deviation by 8.45 mg/dl (<i>p</i> = 0.01), decreased incidence of DKA hospitalization, and a decrease in weight by 3.16 kg (<i>p</i> = 0.007). (4) Conclusions: As more data emerges on cardiovascular and renal benefits of long acting GLP-1 in type 2 diabetes, there have been no reported outcomes in T1DM. Our study is the first to demonstrate glycemic and metabolic benefits of this class of medication as an adjunct therapy to insulin in T1DM, and safety of its use over an average of 1.5–2 years’ time. This study represents real life experience and the data warrants confirmation by additional prospective studies. |
| first_indexed | 2024-03-11T06:37:55Z |
| format | Article |
| id | doaj.art-892d22491c5a4d8b9f093a1ac02449cd |
| institution | Directory Open Access Journal |
| issn | 2673-396X |
| language | English |
| last_indexed | 2024-03-11T06:37:55Z |
| publishDate | 2023-02-01 |
| publisher | MDPI AG |
| record_format | Article |
| series | Endocrines |
| spelling | doaj.art-892d22491c5a4d8b9f093a1ac02449cd2023-11-17T10:46:55ZengMDPI AGEndocrines2673-396X2023-02-01419310110.3390/endocrines4010008Evaluating the Efficacy and Safety of Long-Acting GLP-1 Receptor Agonists in T1DM PatientsDeene Mohandas0Jamie Calma1Catherine Gao2Marina Basina3Division of Endocrinology, Gerontology, and Metabolism, Department of Medicine, Stanford University School of Medicine, Stanford, CA 94305, USADivision of Cardiovascular Medicine, Department of Medicine, Stanford University School of Medicine, Stanford, CA 94305, USADivision of Endocrinology, Gerontology, and Metabolism, Department of Medicine, Stanford University School of Medicine, Stanford, CA 94305, USADivision of Endocrinology, Gerontology, and Metabolism, Department of Medicine, Stanford University School of Medicine, Stanford, CA 94305, USA(1) Background: Glucagon-like peptide 1 receptor agonists (GLP-1 RA) are a class of therapeutic agents that mimic the endogenous incretin hormone GLP-1. While this class of agents is not approved for Type 1 Diabetes (T1DM) due to concern of increased diabetic ketoacidosis (DKA) risk, long-acting GLP-1 medications are being commonly prescribed off label for T1DM in clinical practice. Several studies addressed the efficacy and safety of short-acting GLP-1 agonists therapy in patients with T1DM, but the data on long-acting agents are lacking. In our study, we aim to fill in this gap and help healthcare providers in their clinical decision making on the use of these agents for T1DM patients. (2) Methods: We conducted a retrospective chart review of T1DM patients on a long-acting GLP-1 for at least six months. Our retrospective chart review included information starting two years prior to starting GLP-1, and six or more months after starting GLP-1. Parameters collected included HbA1c, 14-day Continuous Glucose Monitor (CGM) and blood glucose (BG) data, and metabolic data (weight, systolic and diastolic blood pressure, and cholesterol levels). Statistical analysis was conducted using paired t-tests on R and Excel with α of 0.05. (3) Results: Our cohort consisted of 54 participants with T1DM on a long-acting GLP-1 (semaglutide, dulaglutide, exenatide extended-release [ER], albiglutide). Mean GLP-1 treatment duration was 23.85 ± 15.46 months. HbA1c values decreased significantly by an average of 0.71% percentage points (%-points, <i>p</i> = 0.002) comparing pre-therapy vs. on GLP-1 treatment. Similarly, for pre-therapy vs. on GLP-1 treatment values, CGM results were significant for increased time in range by 12.15%-points (<i>p</i> = 0.0009) showing a decreased average time in hyperglycemia (BG > 180 mg/dL) by a mean difference of 11.97%-points (<i>p</i> = 0.006), decreased 14-day mean BG by 19 mg/dl (<i>p</i> = 0.01), decreased 14-day BG standard deviation by 8.45 mg/dl (<i>p</i> = 0.01), decreased incidence of DKA hospitalization, and a decrease in weight by 3.16 kg (<i>p</i> = 0.007). (4) Conclusions: As more data emerges on cardiovascular and renal benefits of long acting GLP-1 in type 2 diabetes, there have been no reported outcomes in T1DM. Our study is the first to demonstrate glycemic and metabolic benefits of this class of medication as an adjunct therapy to insulin in T1DM, and safety of its use over an average of 1.5–2 years’ time. This study represents real life experience and the data warrants confirmation by additional prospective studies.https://www.mdpi.com/2673-396X/4/1/8GLP-1type 1 diabetesadjunct therapy to insulinsemaglutide |
| spellingShingle | Deene Mohandas Jamie Calma Catherine Gao Marina Basina Evaluating the Efficacy and Safety of Long-Acting GLP-1 Receptor Agonists in T1DM Patients Endocrines GLP-1 type 1 diabetes adjunct therapy to insulin semaglutide |
| title | Evaluating the Efficacy and Safety of Long-Acting GLP-1 Receptor Agonists in T1DM Patients |
| title_full | Evaluating the Efficacy and Safety of Long-Acting GLP-1 Receptor Agonists in T1DM Patients |
| title_fullStr | Evaluating the Efficacy and Safety of Long-Acting GLP-1 Receptor Agonists in T1DM Patients |
| title_full_unstemmed | Evaluating the Efficacy and Safety of Long-Acting GLP-1 Receptor Agonists in T1DM Patients |
| title_short | Evaluating the Efficacy and Safety of Long-Acting GLP-1 Receptor Agonists in T1DM Patients |
| title_sort | evaluating the efficacy and safety of long acting glp 1 receptor agonists in t1dm patients |
| topic | GLP-1 type 1 diabetes adjunct therapy to insulin semaglutide |
| url | https://www.mdpi.com/2673-396X/4/1/8 |
| work_keys_str_mv | AT deenemohandas evaluatingtheefficacyandsafetyoflongactingglp1receptoragonistsint1dmpatients AT jamiecalma evaluatingtheefficacyandsafetyoflongactingglp1receptoragonistsint1dmpatients AT catherinegao evaluatingtheefficacyandsafetyoflongactingglp1receptoragonistsint1dmpatients AT marinabasina evaluatingtheefficacyandsafetyoflongactingglp1receptoragonistsint1dmpatients |